Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a company primarily focused on the manufacturing and distribution of various pharmaceutical goods. Their operations span the production and sale of active pharmaceutical ingredients (APIs), finished drug formulations, and empty capsules for medical use. The company's existing product line encompasses treatments for a variety of conditions, including anti-infective agents, antihypertensives for blood pressure management, medications for digestive system health, and respiratory preparations. Beyond its current offerings, AngLiKang is also deeply involved in drug research and development. Their R&D efforts are concentrated on creating new therapies, with a particular emphasis on oral cephalosporin antibiotics, as well as treatments for cardiovascular, renal (kidney), and central nervous system diseases. The company was established in 2001 and maintains its headquarters in Shengzhou, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA